Benzyl γ,γ-dimethyl-β-oxovalerate | 77902-92-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Benzyl γ,γ-dimethyl-β-oxovalerate
• 英文别名: benzyl 4,4-dimethyl-3-oxopentanoate；pivaloylacetic acid benzyl ester
• CAS: 77902-92-2
• 化学式: C₁₄H₁₈O₃
• 分子量: 234.295
• InChiKey: QGEHUMRFFRWNRZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  17
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  Benzyl γ,γ-dimethyl-β-oxovalerate 在 N-溴代丁二酰亚胺(NBS) 作用下， 以 various solvent(s) 为溶剂， 反应 1.0h， 以88%的产率得到2-Bromo-4,4-dimethyl-3-oxo-pentanoic acid benzyl ester
  参考文献：
  名称：

  使用N-卤代琥珀酰亚胺在离子液体中高效进行β-二羰基化合物和环酮的α-卤化的绿色方法

  摘要：

  室温离子液体（ILs）用作绿色可循环使用的反应介质，用于在没有催化剂的情况下以极好的收率将1,3-二酮，β-酮酸酯和环状酮与N-卤代琥珀酰亚胺进行α-单卤代反应。回收的离子液体以一致的活性重复使用五到六次。

  DOI：

  10.1016/j.tetlet.2005.11.141
• 作为产物：
  描述：

  乙醇酸苯甲酯 在 Bis(3-morpholinylpropyl)phenylphosphine 作用下， 以 二氯甲烷 为溶剂， 反应 0.75h， 生成 Benzyl γ,γ-dimethyl-β-oxovalerate
  参考文献：
  名称：

  Versatile .beta.-ketoester and .beta.-ketonitrile synthesis through sulfide contraction

  摘要：

  DOI：

  10.1021/jo00329a017

文献信息

• [EN] HETEROCYCLIC ANTI-VIRAL COMPOUNDS COMPRISING METABOLIZABLE MOIETIES AND THEIR USES<br/>[FR] COMPOSES ANTIVIRAUX HETEROCYCLIQUES COMPORTANT DES GROUPES FONCTIONNELS METABOLISABLES ET LEURS UTILISATIONS
  申请人：RIGEL PHARMACEUTICALS INC

  公开号：WO2005097760A1

  公开（公告）日：2005-10-20

  The present invention relates to substituted prodrug and compositions thereof useful for treating or preventing Hepatitis C virus (HCV) infections. In particular, the present invention relates to prodrugs of substituted diphenyl-, diheteroaryl- and mixed phenyl heteroaryl substituted five-membered heterocycle compounds, compositions comprising the compounds and the use of such compounds and compositions to inhibit HCV replication and/or proliferation as a therapeutic approach towards the treatment and/or prevention of HCV infections in humans and animals.

  本发明涉及替代前药及其组合物，用于治疗或预防丙型肝炎病毒（HCV）感染。具体而言，本发明涉及替代二苯基、二杂环芳基和混合苯基杂环芳基替代的五元杂环化合物的前药，包含这些化合物的组合物以及利用这些化合物和组合物来抑制HCV复制和/或增殖作为治疗方法，以治疗和/或预防人类和动物中的HCV感染。
• [EN] COMPOUNDS HAVING TAFIa INHIBITORY ACTIVITY<br/>[FR] COMPOSES AYANT UNE ACTIVITE INHIBITRICE DU TAFIA
  申请人：TAISHO PHARMA CO LTD

  公开号：WO2011034215A1

  公开（公告）日：2011-03-24

  The present invention provides compounds having superior TAFIa inhibitory activity. They are dihydroimidazoquinoline compounds represented by the following formula (I) or pharmaceutically acceptable salts thereof: (I) wherein R is a hydrogen atom or a C1-10 alkyl group; R1 is a hydrogen atom, a C1-10 alkyl group, a C3-8 cycloalkyl group or a substituent having the structure represented by the following formula Ia or Ib: (Ia) (Ib) where R3 is a C1-6 alkyl group; R4 is a C1-6 alkyl group, a C3-8 cycloalkyl group, or a benzyl group; and R2 is a hydrogen atom or a substituent having the structure represented by the following formula Ic or Id:(Ic) (Id)

  本发明提供了具有优越的TAFIa抑制活性的化合物。它们是由以下式(I)表示的二氢咪唑喹啉化合物或其药学上可接受的盐：(I)其中R是氢原子或C1-10烷基基团；R1是氢原子、C1-10烷基基团、C3-8环烷基基团或具有以下式Ia或Ib所代表的结构的取代基：(Ia) (Ib)其中R3是C1-6烷基基团；R4是C1-6烷基基团、C3-8环烷基基团或苄基；R2是氢原子或具有以下式Ic或Id所代表的结构的取代基：(Ic) (Id)
• Bismuth(III) Chloride-Catalyzed Highly Efficient Transesterification of β-Keto Esters
  作者：Gowravaram Sabitha、Rangavajjula Srinivas、Peddabuddi Gopal、M. Bhikshapathi、Jhillu Singh Yadav

  DOI：10.1002/hlca.201000113

  日期：2011.1

  Bismuth(III) chloride was found to be an efficient catalyst for the transesterification of a variety of β‐keto esters with a wide range of alcohols to afford transesterified products in good to high yields in short reaction times (see Table).

  发现氯化铋是一种有效的催化剂，可用于多种β-酮酯与多种醇的酯交换反应，从而在较短的反应时间内以高收率获得高收率的酯交换产物（见表）。
• Heterocyclic anti-viral compounds comprising metabolizable moieties and their uses
  申请人：Singh Rajinder

  公开号：US20050239751A1

  公开（公告）日：2005-10-27

  The present invention relates to substituted prodrug and compositions thereof useful for treating or preventing Hepatitis C virus (HCV) infections. In particular, the present invention relates to prodrugs of substituted diphenyl-, diheteroaryl- and mixed phenyl heteroaryl substituted five-membered heterocycle compounds, compositions comprising the compounds and the use of such compounds and compositions to inhibit HCV replication and/or proliferation as a therapeutic approach towards the treatment and/or prevention of HCV infections in humans and animals.

  本发明涉及代替前药及其组合物，用于治疗或预防丙型肝炎病毒（HCV）感染。具体而言，本发明涉及取代二苯基、双杂环芳基和混合苯基杂芳基取代的五元杂环化合物的前药，包括该化合物的组合物，以及使用这些化合物和组合物来抑制HCV复制和/或增殖，作为治疗和/或预防人类和动物HCV感染的治疗方法。
• COMPOUNDS HAVING TAFIa INHIBITORY ACTIVITY
  申请人：Amada Hideaki

  公开号：US20120172598A1

  公开（公告）日：2012-07-05

  The present invention provides compounds having superior TAFIa inhibitory activity. They are dihydroimidazoquinoline compounds represented by the following formula (I) or pharmaceutically acceptable salts thereof: wherein R is a hydrogen atom or a C 1-10 alkyl group; R 1 is a hydrogen atom, a C 1-10 alkyl group, a C 3-8 cycloalkyl group or a substituent having the structure represented by the following formula Ia or Ib: where R 3 is a C 1-6 alkyl group; R 4 is a C 1-6 alkyl group, a C 3-8 cycloalkyl group, or a benzyl group; and R 2 is a hydrogen atom or a substituent having the structure represented by the following formula Ic or Id:

  本发明提供了具有优越的TAFIa抑制活性的化合物。它们是由以下化学式(I)表示的二氢咪唑喹啉化合物或其药学上可接受的盐：其中R是氢原子或C1-10烷基；R1是氢原子、C1-10烷基、C3-8环烷基或具有以下化学式Ia或Ib表示的取代基：其中R3是C1-6烷基；R4是C1-6烷基、C3-8环烷基或苄基；R2是氢原子或具有以下化学式Ic或Id表示的取代基：